Heron Therapeutics Management
Management criteria checks 2/4
Heron Therapeutics' CEO is Craig Collard, appointed in Apr 2023, has a tenure of 1.75 years. directly owns 0.18% of the company’s shares, worth €417.35K. The average tenure of the management team and the board of directors is 1.6 years and 3.3 years respectively.
Key information
Craig Collard
Chief executive officer
US$5.5k
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 1.8yrs |
| CEO ownership | 0.2% |
| Management average tenure | 1.6yrs |
| Board average tenure | 3.3yrs |
Recent management updates
Recent updates
CEO
Craig Collard (58 yo)
1.8yrs
Tenure
US$5,486
Compensation
Mr. Craig Alexander Collard serves as Chief Executive Officer at Heron Therapeutics, Inc. since April 3, 2023 and its Director since February 2023. He had been Chief Executive Officer of Veloxis Pharmaceut...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 1.8yrs | US$5.49k | 0.18% € 417.4k | |
| Executive VP & CFO | 1.6yrs | US$1.76m | 0.071% € 169.0k | |
| Executive VP & Chief Development Officer | 1.6yrs | US$1.71m | 0.068% € 161.4k | |
| Vice President of Marketing | 1.4yrs | no data | no data | |
| Senior Vice President of Human Resources | 9.3yrs | no data | no data | |
| Senior Vice President of Oncology Care Franchise & Commercial Operations | 2yrs | no data | no data | |
| Chief Business Officer | less than a year | no data | no data | |
| Executive Director | no data | no data | no data |
1.6yrs
Average Tenure
55yo
Average Age
Experienced Management: AXD2's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 1.9yrs | US$5.49k | 0.18% € 417.4k | |
| Independent Director | 11yrs | US$11.02m | 0.034% € 81.2k | |
| Independent Director | 8.6yrs | US$70.51k | 0.034% € 81.7k | |
| Director | less than a year | no data | no data | |
| Independent Director | 3.3yrs | US$65.63k | 0.035% € 82.8k | |
| Independent Chairman | 1.9yrs | US$545.53k | 0.0062% € 14.8k | |
| Independent Director | 3.3yrs | US$55.00k | 0.035% € 82.8k |
3.3yrs
Average Tenure
57yo
Average Age
Experienced Board: AXD2's board of directors are considered experienced (3.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/21 01:21 |
| End of Day Share Price | 2025/01/21 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Heron Therapeutics, Inc. is covered by 18 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| Jonathan Aschoff | Brean Capital |
| Jonathan Aschoff | B. Riley Wealth |